BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:24 2024-05-01 am EDT			5-day change	1st Jan Change
11.5 ^GBX	0.00%		0.00%	+9.52%

Apr. 17	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN
Apr. 17	BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	MT

Bivictrix selects final sequences for lead tumour programme

November 30, 2023 at 07:10 am EST

Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focused on cancer therapies - Says final sequences have been selected for its second programme BVX002, an antibody drug conjugate or ADC targeting solid tumour indications. Emerging data identifies high-grade serous ovarian cancer as one of the lead indications. Company says it is on track to identify the development lead in 2024. Says findings represent "significant unmet need and commercial potential for BVX002".

Chief Executive Officer Tiffany Thorn says: "ADCs have demonstrated incredible promise as an alternative therapeutic option to current monotherapies and combination therapies across difficult-to-treat cancers, backed by high specificity, versatility and selectivity. We have been encouraged by BiVictriX's progress to date in our lead BVX001 programme for the treatment of Acute Myeloid Leukaemia and are also pleased by the further development and expansion of our proprietary ADC pipeline."

Current stock price: 11.25 pence, up 2.3% in London on Thursday

12-month change: down 25%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about BiVictriX Therapeutics Plc

Bivictrix granted FDA orphan drug status for rare cancer treatment	Apr. 17	AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	Apr. 17	MT
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	Dec. 05	CI
Bivictrix selects final sequences for lead tumour programme	Nov. 30	AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	Nov. 30	CI
BiVictriX patent boost; 4Global deal extended	Nov. 15	AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	Nov. 15	MT
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	Nov. 15	RE
Bivictrix says BVX001 increases survival rates by more than double	23-10-12	AN
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	23-10-12	MT
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	23-10-12	RE
Bivictrix hires new CFO as Alex Hughes steps down after seven months	23-10-03	AN
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	23-10-03	MT
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	23-10-03	CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	23-10-03	CI
AEW UK REIT appoints new chair; Oberon raises money	23-09-19	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	23-09-19	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-19	CI
AIM WINNERS & LOSERS: Jadestone Energy up on Montara repairs progress	23-08-23	AN
Bivictrix Therapeutics granted US patent for cancer drug BVX001	23-08-23	AN
BiVictriX Therapeutics Secures US Patent for Lead Asset	23-08-23	MT
Bivictrix Therapeutics raises GBP2.1 million through fundraise	23-07-19	AN
Bivictrix to raise more than GBP2 million via placing	23-07-19	AN
Bivictrix Therapeutics hails positive data in final leukaemia study	23-07-17	AN
Bivictrix Therapeutics hails positive leukaemia test results	23-06-19	AN

Chart BiVictriX Therapeutics Plc

Duration

Period

More charts

Company Profile

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâs novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-09-17 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.115 GBP

Average target price

0.66 GBP

Spread / Average Target

+473.91%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIVICTRIX THERAPEUTICS PLC	+9.52%	11.89M
IQVIA HOLDINGS INC.	+0.19%	42.19B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+5.63%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-23.20%	18.2B
MEDPACE HOLDINGS, INC.	+27.50%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.93%	11.76B
UNITED THERAPEUTICS CORPORATION	+15.50%	10.4B
BIO-TECHNE CORPORATION	-4.78%	9.94B

Other Biotechnology & Medical Research